Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader ...

Tiziana Life Sciences to Present at the Bio International ConventionNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 ...

Tiziana Life Sciences, Ltd. has announced the publication of a review article in Nature Reviews Neurology, which highlights the potential of its lead drug candidate, intranasal foralumab ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

1, 2 About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...